Lee's Pharmaceutical Company (00950.HK) was increased by 147,500 shares by Executive Director Li Yeni
Gelonghui, May 9 | According to the Stock Exchange's latest equity disclosure data, from May 2 to May 3, 2024, Lee's Pharmaceuticals (00950.HK) was granted an increase of 147,500 shares at an average price of HK$1.1447-1.18 per share on the market, involving approximately HK$170,000. After increasing her holdings, Li Ye-ni's latest shareholding was 127,099,625 shares, and the shareholding ratio increased from 21.56% to 21.58%.
Lee's Pharmaceutical Company (00950.HK) received 7,000 additional shares of common shares worth approximately HK$7,695.1 by Li Yeni
On May 8, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 8, Lee Ye-ni increased her share holdings of $Lee's Pharmaceuticals (00950.HK) by $7,000 at an average price of HK$1.0993 per share on April 30, worth about HK$7,695.1. After the increase in her holdings, Li Yeni's latest shareholding was 127 million shares, with a good position ratio of 21.56%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Director and chief of a listed company
Lee's Pharmaceuticals (00950.HK) received 114,000 additional shares of common stock from Lee Ye-ni, worth approximately HK$135,500
On May 8, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 8, Lee Ye-ni increased her shareholding of $Lee's Pharmaceuticals (00950.HK) by $114,000 at an average price of HK$1.1447 per share on May 2, worth about HK$130,500. After increasing her holdings, Li Yeni's latest shareholding was 127 million shares, and the good position ratio rose from 21.56% to 21.58%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed companies
Lee's Pharmaceuticals (00950.HK) received 33,500 additional shares of common stock from Lee Ye-ni, worth approximately HK$39,500
On May 8, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 8, Lee Ye-ni increased her share holdings of $Lee's Pharmaceuticals (00950.HK) by $33,500 at an average price of HK$1.18 per share on May 3, worth about HK$39,500. After the increase in her holdings, Li Yeni's latest shareholding was 127 million shares, with a good position ratio of 21.58%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. directors and top executives of listed companies,
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Lee's Pharmaceutical's 2023 Profit Slumps 67%
Lee's Pharmaceutical Holdings (HKG:0950) recorded a 67% decline in attributable profit for the year ended Dec. 31, 2023, to HK$16.7 million from HK$51.3 million in 2022, a Friday filing on the Hong Ko
李氏大藥廠:2023年年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
LEE'S PHARM To Go Ex-Dividend On May 28th, 2024 With 0.01 HKD Dividend Per Share
March 27th - $LEE'S PHARM(00950.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.01 HKD dividend per share on June 17th, 2024. The ex-dividend
Lee's Pharmaceuticals (00950) will pay a final dividend of HK$0.01 per share on June 17
Lee's Pharmaceutical (00950) announced that it will be distributed on June 17, 2024 until December 2023...
Lee's Pharmaceuticals (00950.HK): Net profit of HK$16.698 million decreased by 67.4% year-on-year in 2023
Gelonghui, March 26, 丨 Lee's Pharmaceutical (00950.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$1,053 million, down 14.6% year on year; profit attributable to company owners was approximately HK$166.98 million, a decrease of 67.4% year on year; basic profit per share was HK2.84 cents, with a proposed final dividend of 1 HK cent per share. During the reporting period, the Group recorded gross profit of HK$551 million, a decrease of 28.5% over the previous year, in line with the decline in sales. The Group's gross margin for the year was 52.4%, down 10.1 from 62.5% in 2022
李氏大藥廠:截至二零二三年十二月三十一日止年度全年業績公佈
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Lee's Pharmaceutical Company (00950.HK) plans to hold a board meeting on March 26 to approve the annual results
Glonghui, March 14, 丨 Lee's Pharmaceutical (00950.HK) announced that the company's board of directors meeting will be held on March 26, 2024 (Tuesday) on the 1st floor of Building 20E, Science Park Phase III Science Park East, Shatin, New Territories, Hong Kong to review (including) and approve (if deemed appropriate) the publication of the company's and its subsidiaries' annual results announcements for the year ended 31 December 2023 and consider the proposed final dividend (if any).
LEE'S PHARM: Notice of Board Meeting
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
No Data